Apple’s ambitious effort to bring noninvasive glucose monitoring to the Apple Watch may have reached a critical turning point, according to a new report. The project, which has been in development for years, recently underwent a leadership transition that insiders view as a strong signal of progress. The change moves oversight from platform architecture chief Tim Millet to Zongjian Chen, the senior engineering leader in charge of Apple’s Advanced Technologies Group and hardware projects like modems. Within the company, Chen is known as someone who can deliver, and his involvement suggests that the technology could be moving closer to a consumer-grade implementation.
Background on Apple’s Glucose Monitoring Project
First conceived during the Steve Jobs era, Apple’s noninvasive glucose monitoring project has been a moonshot goal for the company for over a decade. The aim is to develop sensors that can detect elevated blood sugar levels without requiring finger pricks or blood draws—a breakthrough that would transform diabetes management. The technology relies on optical sensors that measure glucose levels through the skin, a method that has proven extremely difficult to perfect due to the complex nature of glucose measurement and the need for high accuracy in a wearable form factor.
Apple has been working on this project for years, filing numerous patents related to glucose monitoring and investing heavily in research and development. The company has reportedly tested prototypes in secret facilities and conducted clinical trials to validate the technology’s accuracy. However, the path to a reliable, noninvasive, and miniaturized sensor has been fraught with challenges, including signal interference, calibration issues, and the need to meet strict medical device regulations.
The Leadership Shift and Its Significance
According to multiple reports, Apple recently shifted oversight of the glucose monitoring project from Tim Millet, who leads platform architecture, to Zongjian Chen. Chen oversees the Advanced Technologies Group, which works on cutting-edge hardware and technologies, including modem development. This move is seen as a positive development because Chen has a reputation within Apple for delivering complex projects to production. The transition suggests that the project may have passed a key technical hurdle, allowing Chen to focus on scaling the technology for commercial use.
While it remains unclear exactly what milestone was achieved, the change in leadership is often interpreted as a sign that the project is entering a new phase—from pure research and development to engineering for mass production. Millet is known for his work on Apple’s custom silicon, including the A-series and M-series chips, so his involvement may have centered on the underlying sensor architecture. Chen, with his history of managing demanding hardware programs, is better suited to shepherd the technology through the final stages of development.
Challenges of Noninvasive Glucose Monitoring
Developing a noninvasive glucose monitor is one of the hardest challenges in wearable technology. Current methods for glucose monitoring require either a finger prick to draw blood or a continuous glucose monitor (CGM) that uses a tiny sensor inserted under the skin. Both approaches are invasive and can be inconvenient for the millions of people with diabetes who need to check their glucose levels multiple times a day.
Noninvasive methods attempt to measure glucose through the skin using various techniques, such as optical spectroscopy, Raman spectroscopy, or impedance spectroscopy. Each method has its own set of difficulties: optical sensors can be affected by skin pigmentation, temperature, and hydration; Raman signals are weak and require bulky equipment; and impedance measurements are sensitive to movement and interference. Apple has reportedly focused on a method based on silicon photonics, which uses light to measure glucose levels. This approach has shown promise in research but has yet to be proven in a consumer device.
Beyond the technical hurdles, regulatory approval is another major barrier. Medical devices that claim to measure glucose must undergo rigorous testing by agencies like the FDA to ensure accuracy and safety. Even if Apple perfects the sensor, it could take years to navigate the regulatory landscape. Additionally, the company would need to integrate the sensor into the Apple Watch without compromising its existing features, battery life, or design.
Apple’s Broader Health Ambitions
The glucose monitoring project is part of Apple’s larger strategy to make the Apple Watch an essential health device. Over the years, Apple has added features like an electrocardiogram (ECG), blood oxygen monitoring, fall detection, and atrial fibrillation detection. The company has also invested in sleep tracking, fitness tracking, and mental health tools. Noninvasive glucose monitoring would be the most impactful health feature yet, as it would provide continuous, real-time glucose data without needles.
If successful, the feature could help not only people with diabetes but also those with prediabetes or anyone interested in understanding how their diet and activity affect their glucose levels. This aligns with Apple’s vision of proactive health management, where the device alerts users to potential health issues before they become serious. The company also faces competition from other companies working on similar technology, including Samsung, Fitbit, and various startups. However, Apple’s vertical integration—controlling both hardware and software—gives it a potential advantage in delivering a seamless user experience.
Timeline and Future Outlook
Despite the leadership change, industry insiders caution that a consumer-available glucose monitoring Apple Watch is still several years away. Gurman has previously suggested that the feature could debut in the late 2020s or early 2030s. The transfer of project oversight to Chen is an encouraging sign, but it does not guarantee an imminent release. Apple will need to solve remaining technical challenges, ensure regulatory compliance, and integrate the sensor into the Watch’s compact form factor.
Some reports indicate that Apple is exploring a two-step approach: first, offering the sensor as a separate device or a strap accessory, and later integrating it into the Watch itself. This would allow the company to test the technology with early adopters before making it a standard feature. Another possibility is that Apple could launch a dedicated health device, akin to a medical-grade wearable, alongside the Watch.
The long-term potential of this technology is immense. A noninvasive glucose monitor could reduce the burden of diabetes management, prevent dangerous blood sugar spikes and drops, and provide richer data for personalized health insights. It could also open the door to other biochemical monitoring capabilities, such as measuring hydration, lactate, or even drug levels.
While the road ahead remains challenging, the recent leadership change within Apple’s glucose monitoring team is a clear signal that the company believes it is making real progress. For the millions of people living with diabetes, and for the broader tech industry, this project remains one of the most anticipated innovations in wearable health technology. The Apple Watch continues to evolve from a fitness tracker into a comprehensive health companion, and noninvasive glucose monitoring would be its most transformative feature yet.
Source: 9to5Mac News